{
    "root": "34f67d35-7080-d493-e063-6294a90a5cc9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atovaquone",
    "value": "20250512",
    "ingredients": [
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32112"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "ATOVAQUONE",
            "code": "Y883P1Z2LT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_575568"
        }
    ],
    "indications": {
        "text": "atovaquone oral suspension quinone antimicrobial indicated : prevention pneumocystis jirovecii pneumonia ( pcp ) adults adolescents aged 13 years older tolerate trimethoprim\u00ad-sulfamethoxazole ( tmp-smx ) . ( 1.1 ) treatment mild-to-moderate pcp adults adolescents aged 13 years older tolerate tmp-smx . ( 1.2 ) limitations ( 1.3 ) : treatment severe pcp ( alveolar arterial oxygen diffusion gradient [ ( a-a ) 2 ] > 45 mm hg ) atovaquone studied . efficacy atovaquone subjects failing therapy tmp\u00ad smx also studied .",
        "doid_entities": [
            {
                "text": "pneumocystis jirovecii pneumonia (DOID:11339)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11339"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "prevention pcp : 1,500 mg ( 10 ml ) daily food ( 2.1 ) treatment pcp : 750 mg ( 5 ml ) twice daily food 21 days ( 2.2 ) supplied bottles : bottle : shake bottle gently . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "atovaquone oral suspension usp ( bright yellow , tutti frutti flavored ) containing 750 mg atovaquone per 5 ml . bottle 210 ml child-resistant cap ( ndc 42239-001-08 ) . store 15\u00b0c 25\u00b0c ( 59\u00b0f 77\u00b0f ) . freeze . dispense tight container defined usp . unit dose cup 5 ml ( ndc 42239-001-17 ) . store 15\u00b0c 25\u00b0c ( 59\u00b0f 77\u00b0f ) . freeze .",
    "adverseReactions": "atovaquone oral suspension contraindicated patients develop history hypersensitivity ( e.g . , angioedema , bronchospasm , throat tightness , urticaria ) atovaquone components atovaquone oral solution .",
    "indications_original": "Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim\u00ad-sulfamethoxazole (TMP-SMX). ( 1.1 ) Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 ) Limitations of Use ( 1.3 ): Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2] >45 mm Hg) with atovaquone has not been studied. The efficacy of atovaquone in subjects who are failing therapy with TMP\u00ad SMX has also not been studied.",
    "contraindications_original": "Prevention of PCP: 1,500 mg (10 mL) once daily with food ( 2.1 ) Treatment of PCP: 750 mg (5 mL) twice daily with food for 21 days ( 2.2 ) Supplied in Bottles: Bottle: Shake bottle gently before use. ( 2.3 )",
    "warningsAndPrecautions_original": "Atovaquone oral suspension USP (bright yellow, tutti frutti flavored) containing 750 mg atovaquone per 5 mL.\n                  \n                     Bottle of 210 mL with child-resistant cap (NDC 42239-001-08). Store at 15\u00b0C to 25\u00b0C (59\u00b0F to 77\u00b0F).\n  \n   Do not freeze. Dispense in tight container as defined in USP.\n \n  \n                     Unit dose cup of 5 mL (NDC 42239-001-17). Store at 15\u00b0C to 25\u00b0C (59\u00b0F to 77\u00b0F). Do not freeze.",
    "adverseReactions_original": "Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral solution.",
    "drug": [
        {
            "name": "Atovaquone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_575568"
        }
    ]
}